NCT01005797View on ClinicalTrials.gov

Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers

PHASE1CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

November 30, 2009

Primary Completion Date

March 31, 2014

Study Completion Date

January 31, 2017

Conditions
Renal CancerNon Small Cell Lung Cancer (NSCLC)Soft Tissue Sarcoma
Interventions
DRUG

Panobinostat (LBH589), Sorafenib

Starting dose of sorafenib: 400 mg bid on Day 1-28 of each 28-day cycle; of LBH589: 15 mg on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of each 28-day cycle. Administered simultaneously.

Trial Locations (1)

29425

Medical University of South Carolina Hollings Cancer Center, Charleston

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
lead

Medical University of South Carolina

OTHER

collaborator

Novartis Pharmaceuticals

INDUSTRY